(Left to right: Linlu Tseng, Ph.D., Manager of Business Development at Mycenax; Pei-Chin Tsai, Ph.D., Director of Pharmaceutical Development at Mycenax; Pei-Jiun Chen, Ph.D., CEO and President of Mycenax; Masa Fujiwara, D.V.M., President of RIN Institute; Jamie Hung, CEO of Krisan Biotech; and Wei-I Chou, Ph.D., Associate Vice President of Pharmaceutical Development at Mycenax.)
Taipei, Taiwan — Jun, 16, 2025
Mycenax Biotech Inc. (TWO:4726) announces the signing of a Letter of Intent (LOI) with Japan-based RIN Institute Inc., establishing a strategic collaboration to incorporate RIN’s proprietary antibody-drug conjugate (ADC) linker technology into Mycenax’s CDMO services.
Under the terms of the CDMO business license agreement, Mycenax and Krisan Biotech, Mycenax’s ADC Alliance, will receive an exclusive license to use RIN’s proprietary linker patents in EU, US, China, and Japan, etc.
RIN's proprietary linker has demonstrated stronger anti-tumor effects compared to existing linkers, confirming that it can be applied to cancer cell membrane-targeted antibodies and that it is highly stable in serum. Based on the results, RIN filed a patent application for this proprietary linker technology in November 2024.
This exclusive access will enable Mycenax to deliver differentiated and competitive ADC solutions to global pharmaceutical partners, enhancing both development outcomes and manufacturing efficiency.
In addition to this agreement, Mycenax is contracted to manufacture the investigational drug for RIN’s lead pipeline anti-TMEM180 antibody (Phase 1 study is currently underway). Mycenax has also successfully manufactured a high-quality ADC (DAR8) for Rin’s subsequent pipeline anti-IF-ADC that will employ this proprietary linker.
As the ADC field continues to grow rapidly, this exclusive partnership will not only strengthen Mycenax’s service offerings but also establish both Mycenax and RIN as leaders in the evolving global ADC landscape.
For further information, please refer to RIN’s official announcement.
About RIN
RIN was established in January 2016, for development of anti-cancer antibody drugs both for therapeutic as well as diagnostic uses based upon the research results by Dr. Yasuhiro Matsumura, Director of Research and former Chief of Division of Developmental Therapeutics, EPOC, National Cancer Center (NCC). In March of the same year, RIN was certified as a spin-out Biotech from NCC. RIN’s research laboratory is a research base to promote efficient collaboration with NCC, and R&D projects of ADCs and a novel potent thrombolytic fusion protein have been advanced. In January 2023, RIN started Phase 1 trial of their lead pipeline, a humanized anti-TMEM180 antibody at the NCC. They will accelerate development of new innovative antibodies for anti-cancer drugs and diagnostic drugs with the support of NCC.
About Mycenax
Mycenax is a pioneer in biopharmaceutical CDMO in Taiwan, offering a fully integrated value chain including cell line development, manufacturing processes, analytical methods, and formulation development.
Mycenax operates two GMP-compliant facilities that provide comprehensive manufacturing solutions from drug substance (DS) to drug product (DP) with passed inspections by global regulatory authorities, including the EMA (Europe), PMDA (Japan), and Health Canada. To enhance its global CDMO services, Mycenax partnered with KriSan Biotech in 2022, a provider of antibody, linkers, payloads, and ADC GMP production capabilities. Mycenax and Krisan Biotech are committed to continuously advancing their expertise in site-specific binding, multi-arm structures, dual payloads, and novel functional linkers to meet the growing demand for next-generation ADCs.
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com
(Left to right: Linlu Tseng, Ph.D., Manager of Business Development at Mycenax; Pei-Chin Tsai, Ph.D., Director of Pharmaceutical Development at Mycenax; Pei-Jiun Chen, Ph.D., CEO and President of Mycenax; Masa Fujiwara, D.V.M., President of RIN Institute; Jamie Hung, CEO of Krisan Biotech; and Wei-I Chou, Ph.D., Associate Vice President of Pharmaceutical Development at Mycenax.)
Taipei, Taiwan — Jun, 16, 2025
Mycenax Biotech Inc. (TWO:4726) announces the signing of a Letter of Intent (LOI) with Japan-based RIN Institute Inc., establishing a strategic collaboration to incorporate RIN’s proprietary antibody-drug conjugate (ADC) linker technology into Mycenax’s CDMO services.
Under the terms of the CDMO business license agreement, Mycenax and Krisan Biotech, Mycenax’s ADC Alliance, will receive an exclusive license to use RIN’s proprietary linker patents in EU, US, China, and Japan, etc.
RIN's proprietary linker has demonstrated stronger anti-tumor effects compared to existing linkers, confirming that it can be applied to cancer cell membrane-targeted antibodies and that it is highly stable in serum. Based on the results, RIN filed a patent application for this proprietary linker technology in November 2024.
This exclusive access will enable Mycenax to deliver differentiated and competitive ADC solutions to global pharmaceutical partners, enhancing both development outcomes and manufacturing efficiency.
In addition to this agreement, Mycenax is contracted to manufacture the investigational drug for RIN’s lead pipeline anti-TMEM180 antibody (Phase 1 study is currently underway). Mycenax has also successfully manufactured a high-quality ADC (DAR8) for Rin’s subsequent pipeline anti-IF-ADC that will employ this proprietary linker.
As the ADC field continues to grow rapidly, this exclusive partnership will not only strengthen Mycenax’s service offerings but also establish both Mycenax and RIN as leaders in the evolving global ADC landscape.
For further information, please refer to RIN’s official announcement.
About RIN
RIN was established in January 2016, for development of anti-cancer antibody drugs both for therapeutic as well as diagnostic uses based upon the research results by Dr. Yasuhiro Matsumura, Director of Research and former Chief of Division of Developmental Therapeutics, EPOC, National Cancer Center (NCC). In March of the same year, RIN was certified as a spin-out Biotech from NCC. RIN’s research laboratory is a research base to promote efficient collaboration with NCC, and R&D projects of ADCs and a novel potent thrombolytic fusion protein have been advanced. In January 2023, RIN started Phase 1 trial of their lead pipeline, a humanized anti-TMEM180 antibody at the NCC. They will accelerate development of new innovative antibodies for anti-cancer drugs and diagnostic drugs with the support of NCC.
About Mycenax
Mycenax is a pioneer in biopharmaceutical CDMO in Taiwan, offering a fully integrated value chain including cell line development, manufacturing processes, analytical methods, and formulation development.
Mycenax operates two GMP-compliant facilities that provide comprehensive manufacturing solutions from drug substance (DS) to drug product (DP) with passed inspections by global regulatory authorities, including the EMA (Europe), PMDA (Japan), and Health Canada. To enhance its global CDMO services, Mycenax partnered with KriSan Biotech in 2022, a provider of antibody, linkers, payloads, and ADC GMP production capabilities. Mycenax and Krisan Biotech are committed to continuously advancing their expertise in site-specific binding, multi-arm structures, dual payloads, and novel functional linkers to meet the growing demand for next-generation ADCs.
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com